Wells Fargo Maintains Overweight on Revolution Medicines, Raises Price Target to $167

Benzinga Newsdesk www.benzinga.com Positive 80.3%

Neg 0% Neu 0% Pos 80.3%

Wells Fargo analyst Eva Fortea Verdejo maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target from $144 to $167.